HCPLive

Long-Acting Clotting Agent Approved for Form of Hemophilia

MONDAY, March 31, 2014 (HealthDay News) -- The drug Alprolix has been approved by the US Food and Drug Administration (FDA) as the first long-acting hemophilia B clotting agent, the FDA said in a news release.

The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first hemophilia B remedy designed to require less frequent injections than prior treatments, the FDA said. It was approved to help control and prevent bleeding episodes and to manage bleeding during surgery.

Alprolix was evaluated in clinical studies involving 123 people, ages 12-71, with severe hemophilia B. No safety issues were identified during the trials, the FDA said.

The product is manufactured by Biogen Idec, located in Cambridge, Mass.

More Information


Copyright © 2014 HealthDay. All rights reserved.

Most Popular

Recommended Reading

After undergoing weight-loss surgery, women are significantly less prone to diabetes during pregnancy but twice as likely to deliver smaller-than-normal infants, according to a study published in the Feb. 26 issue of the New England Journal of Medicine.
Addicts' use of a powerful painkiller is driving a large HIV outbreak in Indiana, according to health officials.
Young children are at increased risk of becoming seriously ill with pneumonia -- but unlike in years past, the cause is usually a respiratory virus, according to a study published in the Feb. 26 issue of the New England Journal of Medicine.
The US Centers for Disease Control and Prevention (CDC) advisory committee on immunization practices today approved including Merck's Gardasil 9 vaccine in a list of recommended vaccinations for children and young adults. The vaccine got US Food and Drug Administration (FDA) approval in December, 2014. The vaccine is an improvement on the older version of Gardasil in that it offers protection against 5 more types of Human Papillomavirus (HPV) than the original product.
$vAR$